Drugmakers must face skincare drug price-fixing lawsuit, US judge rules

A federal judge has ruled that 36 drugmakers and executives, including Pfizer, Perrigo, and Sandoz, must face nearly all claims in an antitrust lawsuit brought by 45 U.S. states and territories. The lawsuit alleges a conspiracy to fix prices for 80 generic drugs between 2009 and 2016, with the judge rejecting arguments that the states delayed their claims by citing evidence of the defendants' alleged concealment tactics. This decision allows a significant antitrust case to proceed, potentially leading to substantial liabilities for the pharmaceutical companies involved and impacting the generic drug market.

Analysis

A federal judge has ruled that 36 drugmakers and executives, including Pfizer (PFE) and Perrigo (PRGO), must face nearly all claims in a significant antitrust lawsuit. This decision allows 45 U.S. states and territories to proceed with allegations of price-fixing for 80 generic drugs between 2009 and 2016. The ruling rejects arguments that states delayed their claims, citing evidence of defendants' alleged concealment tactics.

The lawsuit accuses these companies of conspiring to raise prices, limit competition, and allocate customers, particularly for skin ailment medications. Chief Judge Michael Shea highlighted "affirmative acts" by defendants to conceal their alleged collusion, such as "blaming supply" and "falsely citing production costs" for price increases. This indicates the court found sufficient evidence to suggest deliberate misconduct.

This development represents a material legal risk for the implicated pharmaceutical companies, particularly Pfizer and Perrigo, given the moderately negative per-ticker sentiment of -0.7. The continuation of this multi-state antitrust case could lead to substantial financial liabilities, including fines and damages, impacting their future earnings and market valuations. The broader generic drug market may also face increased scrutiny regarding pricing practices.

Key Decisions for Investors

• Investors should closely monitor the legal proceedings for PFE and PRGO, assessing potential financial liabilities and the timeline for resolution.
• Evaluate the current valuations of implicated drugmakers against the backdrop of increased litigation risk and potential reputational damage.
• Consider the broader regulatory environment for the generic drug sector, as this ruling may presage heightened antitrust scrutiny and enforcement actions across the industry.